VICTOR
ASENSI ALVAREZ
Catedrático de Universidad
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (16)
2022
2017
-
Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach
PLoS ONE, Vol. 12, Núm. 9
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2016
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596
2015
-
Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: A randomized clinical trial
Clinical Infectious Diseases, Vol. 60, Núm. 5, pp. 811-820
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
-
Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)
Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5
2014
-
Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2014)
Enfermedades Infecciosas y Microbiologia Clinica Monografias, Vol. 32, Núm. 7, pp. 446e1-446e42
-
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014)
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 7, pp. 447-458
2011
-
No relationship between TNF-α genetic variants and combination antiretroviral therapy-related lipodystrophy syndrome in HIV type 1-infected patients: A case-control study and a meta-analysis
AIDS Research and Human Retroviruses, Vol. 27, Núm. 2, pp. 143-152
2008
-
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092
2007
-
Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin
Antiviral Therapy, Vol. 12, Núm. 4, pp. 469-476
-
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial
AIDS Research and Human Retroviruses, Vol. 23, Núm. 8, pp. 972-982
2005
2004
-
Consensus conference on chronic viral hepatitis and HIV infection: Updated Spanish recommendations
Journal of Viral Hepatitis
2003
-
Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients
Journal of Clinical Microbiology, Vol. 41, Núm. 9, pp. 4421-4423